Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Psoriasis
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Psoriasis
    Fumaric Acid Ester Safe and Effective Against Psoriasis in Patients Receiving Medication for Comorbidities: Presented at EADV - (DGDispatch)
    Infliximab More Effective Than Methotrexate in Patients With Moderate to Severe Plaque Psoriasis: Presented at EADV - (DGDispatch)
    Patients With Psoriasis Experience Improved Quality of Life Following Adalimumab Treatment: Presented at EADV - (DGDispatch)
    Adalimumab Yields Fast and Sustainable Scalp and Nail Results in Patients With Psoriasis: Presented at EADV - (DGDispatch)
    Comorbidities of Psoriasis Create Higher Healthcare Costs: Presented at EADV - (DGDispatch)

    News archive

     Recent webcasts/CME - Psoriasis
    • Using Biologics to Improve Both Physical and Social Function in Rheumatic Diseases
    • Rheumatic Diseases: Using Anti-TNF-alpha Agents to Improve Everyday Patient Function
    • Management of Psoriasis: Update for the Pharmacist
      Exploring Psoriatic Arthritis: Bridging Dermatology and Rheumatology
      Moderate-to-Severe Psoriasis and Psoriatic Arthritis: Reducing the Clinical and Economic Burden Through Effective Treatment Protocols

      Webcasts/CME archive

       Recent cases - Psoriasis
        Therapeutic Effect of Hyperbaric Oxygen in Psoriasis Vulgaris: Two Case Reports and a Review of the Literature
        Exacerbation of Psoriasis with beta-Blocker Therapy
        Concomitant Xeroderma Pigmentosum and Disseminated Small Plaque Psoriasis - The First Case of an Antinomic Association: A Case Report
        Extensive Psoriasis Induced by Pegylated Interferon: A Case Report
        Pulmonary Sarcoidosis Associated with Psoriasis Vulgaris: Coincidental Occurrence or Causal Association? Case Report

        Cases archive
          




        my personal edition > psoriasis > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Tazarotene Gel Improves Fingernail Psoriasis: Presented at WCD

        By Jill Stein
        Special to DG News

        PARIS, FRANCE -- July 2, 2002 -- Evening application of tazarotene 0.1 percent gel to psoriatic fingernails can produce an impressive clinical improvement.

        Dr. Richard K. Scher and colleagues at Columbia-Presbyterian Medical Center in New York, New York, presented the results today at the 20th World Congress of Dermatology (WCD). Their study enrolled 31 patients with psoriasis affecting at least two fingernails.

        Patients were randomised to either tazarotene 0.1 percent gel or vehicle gel. They applied the gel to each target fingernail and the surrounding nail folds every evening for up to 24 weeks. One target fingernail was occluded with polyethylene film during the treatment period. No other medications were allowed on the fingernails.

        All patients were adults with psoriasis that was characterized by at least three of the following: pitting, onycholysis, subungual hyperkeratosis, leukonychia, nail plate crumbling and/or loss, splinter hemorrhages, and nail bed discoloration.

        Patients were ineligible if they had psoriasis for less than six months or if either of their two target fingernails (designated by the investigator) had a positive potassium hydroxide (KOH) or dermatophyte/fungal culture.

        Results showed that tazarotene was consistently more effective than the vehicle gel in reducing onycholysis in occluded nails and nonoccluded nails. Tazarotene was also significantly more effective in reducing pitting in occluded nails. There were no other significant differences between the two groups.

        Five patients (all in the tazarotene group) reported treatment-related adverse events, which included peeling and erythema of proximal nail fold skin, skin irritation, periungual irritation, and paronychia. All such adverse events were mild or moderate.

        The study was sponsored by Allergan Skin Care of Irvine, California.



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send